<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336647</url>
  </required_header>
  <id_info>
    <org_study_id>Ha02-003</org_study_id>
    <nct_id>NCT01336647</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation</brief_title>
  <official_title>An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hatchtech Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hatchtech Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to assess the safety and effectiveness of a product to treat children and
      adults with head lice
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit</measure>
    <time_frame>Follow up visit at days 1, 7 and 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Ha44 Gel</measure>
    <time_frame>From treatment to last visit of the study at 14 days</time_frame>
    <description>The number of subjects with Treatment emergent AEs (TEAEs) related to the study medication will be reported by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Pediculosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A - Low-Dose Ha44 0.37% w/w</intervention_name>
    <description>Low Dose Ha44 Gel applied to scalp and hair for 10 minutes</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B - High Dose Ha44 Gel 0.74% w/w</intervention_name>
    <description>High Dose Ha44 Gel applied to scalp and hair for 10 minutes</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group C - Placebo</intervention_name>
    <description>Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 years of age or older

          -  Body weight of at least 33 pounds

          -  Has an active head lice infestation at Day 0. An active infection is defined as at
             least 3 live lice for the index subject and at least 1 live louse for the other
             household members

          -  Belong to a household of no more than 6 members, except where additional household
             members are &lt; 2 years of age

          -  Belong to a household with an eligible index subject between 2 and 12 years of age
             with active lice infestation

          -  Female subjects must be:

               -  of non-childbearing potential (no history of menstrual periods,
                  post-hysterectomy, or, post-menopausal for at least 2 years) OR,

               -  if of childbearing potential, must have a negative urine pregnancy test prior to
                  treatment and agree to use a highly effective method of contraception from Day 0
                  through the Day 14 visit.

        Exclusion Criteria:

          -  Had treatment for head lice within 14 days prior to Day 0

          -  Has a household member(s) who is infested with lice but is not willing or not eligible
             for enrollment

          -  Has a condition or illness that, in the opinion of the Investigator, may interfere
             with the study results

          -  Has an electrocardiographic abnormality, renal disease or impaired renal function,
             dermatological disease on the face, scalp, ears or neck, or active ophthalmological
             disease, moderate or severe scleral injection with conjunctival erythema or purulent
             discharge or allergic or perennial rhinitis requiring chronic treatment

          -  Has been using hormonal contraception for less than 3 months or is pregnant or
             lactating

          -  Has received systemic corticosteroids within 7 days prior to Day 0 or planned while on
             study

          -  Receiving systemic or topical medication, which in the opinion of the Investigator,
             may interfere with the study results

          -  Has received an investigational agent within 30 days prior to Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Restrepo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universal Biopharma Reserach Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydie Hazan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Axis Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universal BioPharma Research Institute, Inc.</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <results_first_submitted>December 4, 2013</results_first_submitted>
  <results_first_submitted_qc>January 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2015</results_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Ha 44 Gel</title>
          <description>Low-Dose Ha44 Gel 0.37%, it was administered topically for 10 minutes as a single dose.</description>
        </group>
        <group group_id="P2">
          <title>High-Dose Ha44</title>
          <description>High-Dose Ha44 Gel 0.74% it was administered topically for 10 minutes as a single dose</description>
        </group>
        <group group_id="P3">
          <title>Vehicle</title>
          <description>Vehicle Ha44 Gel with no active incident it was administered topically for 10 minutes as a single dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Ha44 Gel</title>
          <description>Low-Dose Ha44 0.37% Gel, topically administered to hair and scalp for 10 minutes</description>
        </group>
        <group group_id="B2">
          <title>High-Dose Ha44</title>
          <description>High-Dose Ha44 0.74% Gel, topically administered to hair and scalp for 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Vehicle</title>
          <description>Vehicle Gel without active ingredient of Ha44.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.7" spread="10.5"/>
                    <measurement group_id="B2" value="15.3" spread="11.3"/>
                    <measurement group_id="B3" value="17.3" spread="13.3"/>
                    <measurement group_id="B4" value="15.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit</title>
        <time_frame>Follow up visit at days 1, 7 and 14 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Ha44</title>
            <description>Ha44 0.37% Gel administered topically to hair and scalp for 10 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Hig Dose Ha44</title>
            <description>Ha44 0.74% Gel administered topically to hair and scalp for 10 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Vehicle Gel without active ingredient administered topically to hair and scalp for 10 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit</title>
          <population>Intent to Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis; 80% power and 0.025 two-sided level of significance for each pairwise active vs. vehicle comparison</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The primary efficacy endpoint was responder rate calculated based on the percentage of subjects who were lice free at all follow-up visits (Days 1, 7 and 14). Because the number of responders and non-responders in the family size&gt;= 5 household members was less than five in at least one of the treatment arms, (Table 14.2.1.5), Fisher’s Exact test was used to compare treatment arms, instead of the CMH test.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <method_desc>The assessment of statistical significance will be done using Hochberg’s modified Bonferroni test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Ha44 Gel</title>
        <description>The number of subjects with Treatment emergent AEs (TEAEs) related to the study medication will be reported by treatment group.</description>
        <time_frame>From treatment to last visit of the study at 14 days</time_frame>
        <population>All subjects who participated</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Ha44</title>
            <description>Low-Dose Ha44 0.37% Gel, administered topically to hair and scalp for 10 minutes.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Ha44</title>
            <description>High-Dose Ha44 0.74% Gel administered topically to hair and scalp for 10 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Vehicle Gel without active ingredient administered topically to hair and scalp for 10 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Ha44 Gel</title>
          <description>The number of subjects with Treatment emergent AEs (TEAEs) related to the study medication will be reported by treatment group.</description>
          <population>All subjects who participated</population>
          <units>participants with treatment related AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Ha44 Gel</title>
          <description>Low-Dose Ha44 0.37% Gel, administered topically to hair and scalp for 10 minutes.</description>
        </group>
        <group group_id="E2">
          <title>High Dose Ha44 Gel</title>
          <description>High-Dose Ha44 0.74% Gel, administered topically to hair and scalp for 10 minutes.</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Vehicle Gel without active ingredient administered topically to hair and scalp for 10 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Manager</name_or_title>
      <organization>Hatchtech Pty Ltd</organization>
      <phone>+61 3 9092 0490</phone>
      <email>tahveninen@hatchtech.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

